A novel fully human anti-PD-1 monoclonal antibody—cemiplimab (formerly known as REGN2810)—is currently evaluated in BCC and CSCC (NCT02383212) [104]. The gene discussed is PDCD1; the disease is skin basal cell carcinoma.